CXCR4 and hepatocellular carcinoma: In orthotopic mouse models of HCC, sorafenib increases the number of F4/80+ TAMs, as well as CD11b + Gr-1+ and CD45+ CXC motif chemokine receptor 4 (CXCR4)+ myeloid cells [188].